SIRT7 and hepatocellular carcinoma: Finally, SIRT7 inhibited the expression of PD-L1 by forming a complex with MEF2D, suggesting that strategies to modulate the activity of SIRT7 may potentially enhance the efficacy of immunotherapies in hepatocellular carcinoma (92).